Trius Therapeutics, Inc. (TSRX) Message Board

Right on my friend.

Sentiment: Strong Buy

Bump

BUMP......

Sentiment: Strong Buy

Shame on you to say I am a liar. You don't know me. In my life when someone has said such things it was because he was the liar. Here it's a MB and I have not insulted anyone. I just expressed my gut feeling after checking more facts. Maybe I am wrong to have sold my shares but I am not a liar. Sorry man I try everyday to be honest. So get a life.

Just Google : Focus Surgery, Inc. develops and commercializes high intensity focused ultrasound products for the treatment of prostate diseases. The company offers Sonablate 500 system, an image-guided acoustic ablation device for treatment planning and monitoring, and targeted and noninvasive tissue treatment. It offers its products through distributors in the United States and internationally. The company was founded in 1996 and is based in Indianapolis, Indiana. Focus Surgery, Inc. operates as a subsidiary of USHIFU, LLC.

Also :

Sonablate® 500 approved to treat Prostate Cancer with High Intensity Focused Ultrasound in Mexico


CHARLOTTE, NC, August 2, 2004 - On July 26, 2004 the Mexican Ministry of Health granted approval to U.S. HIFU, a development company based in Charlotte, NC, for the use of the Sonablate® 500 in Mexico for the treatment of prostate cancer with High Intensity Focused Ultrasound, or HIFU, technology. This is the first HIFU technology officially approved in Mexico.

The Sonablate 500®, developed by Focus Surgery Inc. of Indianapolis, IN, is a noninvasive therapy device that uses the power of ultrasound to destroy deep seated tissue without affecting healthy surrounding tissue. Ultrasound energy is non-ionizing "clean energy" that does not affect tissue surrounding the target zone, as opposed to radiation therapies. The treatment usually can be given in one to three hours on an outpatient basis with epidural anesthesia.

Steve Puckett, Jr., chief executive officer of U.S. HIFU said, "Mexican approval for the Sonablate® 500 marks a new chapter in the fight against prostate cancer in the region. Mexican patients now have access to the most advance prostate cancer treatment available today."

In 2001, the Sonablate® 500 received approval in Europe and Japan. The device is also approved for use in the Dominican Republic.

Although the Sonablate® 500 is only approved for investigational use within the United States U.S. HIFU executives are eager to offer HIFU to as many people as possible. "U.S. HIFU will not rest until this treatment option is available throughout all of the Americas," Puckett said.

The American Cancer Society reported in 2000 that 16.6 men out of 100,000 will die of prostate cancer in Mexico. The mortality rating is only slightly higher in the United States where on average 17.9 of 100,000 men will die of prostate cancer. Early prostate cancer has few symptoms and the only risk factors are age, ethnicity and family history of the disease. Early detection with a digital rectal exam and a blood test to detect levels of prostate-specific antigen (PSA) are essential for being treated successfully.

U.S. HIFU is the exclusive distributor of the Sonablate® 500 in North, Central and South America including island nations of the Caribbean. The company also holds a minority ownership position in Focus Surgery. U.S. HIFU's investment in Focus Surgery will help fund Phase II-III U.S. clinical trials of the Sonablate® 500 which are scheduled to begin later this year.